Johnson & Johnson (JNJ) Price on Solana

With reports of a potential ~$20 billion sale of its DePuy Synthes orthopedics unit to Apollo Global Management putting J&J's MedTech portfolio reshaping front and center, analysts are now scrutinizing whether the stock's substantial recent run has already priced in the upside. JNJ shares trade near $270, up roughly 18% over the past 90 days and more than 58% over the past year, and the consensus fair-value estimate of approximately $270.59 suggests the stock is nearly fully valued at current levels.

A discounted cash-flow model cited by Simply Wall Street offers a more bullish read, pointing to an intrinsic value near $364 and implying meaningful discount to fundamentals. However, analysts note several headwinds that temper the outlook: STELARA's approaching loss of exclusivity, ongoing talc litigation exposure, and the possibility that the favorable oncology data and deal optimism that drove recent gains are already reflected in the price. The DePuy Synthes sale, if completed, would mark a significant step in J&J's effort to concentrate its MedTech segment on higher-growth areas, but the valuation debate centers on how much of that strategic benefit the market has already awarded.

Johnson & Johnson reported updated Phase 3 PAPILLON trial results showing that first-line RYBREVANT (amivantamab) combined with carboplatin-pemetrexed chemotherapy achieved a median overall survival of 34.3 months in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations, compared to 27.9 months for chemotherapy alone — a difference of more than six months. The data were presented at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer. Notably, 76% of patients in the control arm subsequently crossed over to receive second-line amivantamab, which compresses the observed survival gap.

EGFR exon 20 insertion mutations represent roughly 12% of all EGFR mutations and have historically carried poor prognoses, with prior median overall survival estimates of 16–24 months and a five-year survival rate of just 8%. J&J describes amivantamab as a first-in-class bispecific antibody targeting both EGFR and MET receptors, addressing two key pathways of tumor growth and treatment resistance. The 34.3-month result is the longest reported median overall survival in this patient population to date, though the hazard ratio of 0.87 did not reach statistical significance (p=0.307), partly attributed to the high crossover rate in the control arm.

Apollo Global Management is in early discussions to acquire Johnson & Johnson's orthopedics division, DePuy Synthes, at a valuation of roughly $20 billion, according to Bloomberg sources. DePuy Synthes makes implants and surgical instruments for hip, knee, shoulder, trauma, and spine procedures, and generated approximately $9.3 billion in 2025 sales — about 10% of J&J's total revenue and nearly 30% of its MedTech segment. J&J announced the separation plan in October 2025, targeting completion by 2027, and has already recorded $377 million in separation-related costs through the first half of 2026.

The talks remain private and other private equity firms are also evaluating the business, meaning a deal is not guaranteed; J&J could alternatively pursue a spin-off as a standalone public company. JNJ shares were down 0.3% during regular trading at $265.58 but edged 0.5% higher after hours following the report, extending a year-to-date gain of 28%.

Johnson & Johnson shares closed at a record high above $275, extending a seven-session winning streak and lifting the stock 33% year-to-date against the S&P 500's 12% gain. UBS raised its price target to $320 from $280, citing three converging catalysts: top-line growth inflecting from a historical 4–6% compound annual growth rate to 8%-plus through the rest of the decade, the potential for multiple expansion as J&J is rerated back toward growth-stock status, and a deliberate portfolio shift toward higher-margin products. Analysts noted the stock is also attracting defensive rotation from investors stepping back from the AI trade.

On the product side, Darzalex — J&J's blockbuster multiple myeloma therapy — delivered more than $4 billion in Q2 sales, growing close to 18%, with UBS projecting peak annual sales of $22–23 billion as penetration approaches 80% and U.S. patent exclusivity extends to 2029. The immunology segment posted 71% Q2 sales growth. In MedTech, the FDA granted De Novo authorization in July for OTTAVA, J&J's table-integrated surgical robot — the first of its kind approved in the U.S. — which reduces operating-room footprint by 30–50% compared to rival systems and achieved 100% procedural completion in clinical trials. A $5.5 billion talc settlement, pending sufficient claimant participation, has removed what management called a decade-long legal overhang from the investment thesis, clearing a path analysts say the rally has not yet fully priced in.

Johnson & Johnson's latest 13F filing, as of June 30, 2026, discloses equity stakes in 15 biotech and medtech companies with a combined value anchored by its $300.2 million position in Protagonist Therapeutics (PTGX)—the largest holding by a wide margin. Other notable positions include $212 million in Nanobiotix, $89.7 million in MeiraGTx, and $74.4 million in Rapport Therapeutics, with more than half the portfolio concentrated in small-, micro-, and nano-cap names. Relative to J&J's $20.8 billion cash position, the entire portfolio represents a modest strategic overlay rather than a core capital allocation.

Protagonist stands out as the portfolio's most developed holding. Icotyde, a drug co-developed with J&J, launched in March 2026 for moderate-to-severe plaque psoriasis, while additional candidates are in late-stage testing for Crohn's disease, psoriatic arthritis, and ulcerative colitis. The FDA is also reviewing rusfertide for polycythemia vera, with commercialization rights held by Takeda. Protagonist posted a Q2 2026 profit of $162.8 million and holds $849.5 million in cash, and its shares are up roughly 65% year-to-date through late August 2026—a combination of commercial traction, pipeline depth, and financial strength that sets it apart from the more speculative names in J&J's 13F.

Johnson & Johnson is deepening its position in cell therapy by partnering with Sail Biomedicines, a company developing in vivo CAR-T treatments that aim to sidestep the complex manufacturing processes of current cell therapies. Under the deal, J&J will pay Sail an upfront $785 million, with up to $140 million in near-term milestone payments and an acquisition option valued at $2.58 billion. Management acknowledged near-term earnings dilution but characterized the investment as strategically necessary to stay competitive in a CAR-T market projected to grow from $2.69 billion in 2022 to $35.9 billion by 2032.

The partnership is a direct response to pressure from Bristol Myers Squibb, whose Breyanzi franchise targets lymphomas and leukemias. J&J already markets Carvykti for multiple myeloma and is looking to Sail's in vivo approach — which would allow CAR-T cells to be engineered inside the patient's body rather than ex vivo — to expand applications beyond oncology into immune-mediated diseases and improve scalability. J&J's higher hedge fund interest relative to BMS (117 funds versus 74) and lower short-seller exposure suggest the market views J&J's pipeline positioning favorably heading into the next phase of cell therapy competition.

The FDA has approved Johnson & Johnson's Imaavy (nipocalimab) to treat warm autoimmune hemolytic anemia (wAIHA), a rare and potentially life-threatening blood disorder affecting approximately one in 8,000 people. The approval covers patients aged 12 and older who are currently receiving or have previously received steroids, making Imaavy the first treatment specifically approved for this patient population. In a clinical study of 115 adults, about three times as many patients treated with Imaavy achieved sustained improvement in hemoglobin levels after 24 weeks compared with placebo recipients.

Imaavy, an intravenous infusion administered once every four weeks, previously received FDA approval for generalized myasthenia gravis in 2025. J&J has projected the drug could reach more than $5 billion in peak sales across all indications, though analysts characterize the wAIHA approval as an incremental growth opportunity rather than a standalone earnings catalyst. Adoption headwinds include treatment costs, insurance coverage hurdles, and competition from existing therapies.

A Louisiana jury awarded $10 million in a mesothelioma case tied to talc exposure, with Johnson & Johnson found liable for more than $1.20 million of the damages after the court ruled its talc products were unreasonably dangerous and inadequately labeled regarding asbestos risks. The verdict is separate from J&J's proposed $5.5 billion settlement announced in August 2026, which targets approximately 76,000 ovarian cancer claims — mesothelioma cases represent a distinct injury category and remain outside that settlement's scope, indicating J&J's talc legal exposure spans multiple fronts simultaneously.

Analysts view the financial impact of this individual verdict as modest but note that repeated adverse outcomes could erode investor confidence in the company's cash flow resilience. With a projected fair value around $270 per share requiring roughly 7% annual revenue growth through 2029, the bull case for JNJ relies on its expanding oncology and immunology portfolio outweighing ongoing legal overhangs. This Louisiana verdict reinforces that talc litigation remains an active trial risk even as the company pursues a broad settlement on the ovarian cancer track.

Johnson & Johnson has proposed a $5.5 billion settlement to resolve approximately 76,000 ovarian cancer lawsuits tied to its talc-based baby powder products. The deal is not yet final — it requires at least 95% participation from eligible claimants — and payments are structured to begin with up to $3 billion in 2027 with additional installments from 2028 onward. An attorney involved in negotiations noted the total payout could ultimately reach $7 billion or more depending on participation rates, as the headline figure lacks a firm cap.

Bulls argue that converting years of unpredictable litigation into a defined obligation lets J&J refocus on its pharmaceutical and medical-device businesses; the company closed Q2 2026 with roughly $21 billion in cash and is on pace to exceed $100 billion in annual revenue for the first time. The bear case centers on the settlement's non-binding status, cost uncertainty, and the fact that future talc claims are not covered — a federal judge has also signaled skepticism about plaintiffs' ability to prove causation, meaning J&J may be settling from a position of relative legal strength rather than existential pressure.

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, extending the bispecific antibody's label into earlier second-line treatment. The approval is based on Phase 3 MajesTEC-3 data showing the combination reduced the risk of disease progression or death by 83.4% versus standard care (hazard ratio 0.17; p<0.001), with three-year overall survival of 83.3% compared to 65.0% on standard regimens. Safety was manageable, with all cytokine release syndrome events graded 1 or 2 and discontinuation rates comparable across arms.

The approval strengthens J&J's oncology franchise at a commercially significant moment: teclistamab has now reached more than 30,700 patients globally, while its combination partner daratumumab has been used in roughly 830,000 patients, providing an established commercial infrastructure for the new indication. By positioning the combination as "a potential new standard of care" for second-line myeloma — a disease marked by recurring relapses — J&J is targeting a substantially larger addressable patient pool than late-line monotherapy alone. The EC decision follows the drug's earlier approval in Europe as a monotherapy for heavily pre-treated patients and expands the company's bispecific antibody footprint in a competitive oncology segment.